CeriBell, Inc. $CBLL Stock Holdings Lifted by KCM Capital Inc

KCM Capital Inc boosted its holdings in shares of CeriBell, Inc. (NASDAQ:CBLL) by 40.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,400,000 shares of the company’s stock after buying an additional 400,000 shares during the quarter. CeriBell makes up approximately 4.1% of KCM Capital Inc’s holdings, making the stock its 8th largest holding. KCM Capital Inc’s holdings in CeriBell were worth $25,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after acquiring an additional 147,013 shares during the last quarter. Yu Fan raised its position in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after purchasing an additional 130,964 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares in the last quarter. Novo Holdings A S grew its position in CeriBell by 2.3% during the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Millennium Management LLC increased its stake in CeriBell by 41.8% during the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after purchasing an additional 196,299 shares in the last quarter.

CeriBell Trading Down 6.0%

Shares of CBLL opened at $16.82 on Thursday. The firm’s 50-day moving average is $18.54 and its two-hundred day moving average is $19.47. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $638.15 million, a P/E ratio of -10.32 and a beta of 0.77.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. On average, research analysts predict that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Xingjuan Chao sold 39,000 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.90, for a total value of $776,100.00. Following the sale, the chief executive officer directly owned 802,317 shares of the company’s stock, valued at approximately $15,966,108.30. This represents a 4.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William W. Burke sold 2,207 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the transaction, the director owned 23,022 shares of the company’s stock, valued at $456,756.48. This trade represents a 8.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 350,789 shares of company stock valued at $6,946,191 in the last three months. 20.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Canaccord Genuity Group lowered their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.